NCT00975767View on ClinicalTrials.gov

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2014

Conditions
Advanced Malignancies, Non-small Cell Lung Cancer
Interventions
DRUG

MGCD265+erlotinib

MGCD265 and erlotinib administered daily

DRUG

MGCD265+docetaxel

MGCD265 administered daily; docetaxel administered once every 3 weeks

Trial Locations (5)

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

27710

Duke University Medical Center, Durham

48201

Barbara Ann Karmanos Cancer Center, Detroit

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT00975767 - A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter